← Research library

Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis

Comparison in people · 2013

What was studied
1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
Main finding
The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.

Total cholesterol · 7.6 ± 0.3 mmol/L standard care, 6.3 ± 0.5 with two products, 5.8 ± 0.6 with four products. Shared baseline 8.7 ± 0.4. · Both adjunctive groups are marked significant versus standard care. Exact p values are unavailable.

Reported findings and study design

Moscow, December 2011 to June 2012. Standard treatment alone (514), with Ventfort and Cerluten (319), or with those two plus Svetinorm and Endoluten (416). The Russian methods list two oral capsules each per day for three months for Ventfort, Cerluten and Svetinorm when assigned. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified.

Population or model 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.

Results · Russian conference reproduction, pp. 8–10, and matching English edition
MeasureResultComparison, timing and statistics
Total cholesterol7.6 ± 0.3 mmol/L standard care, 6.3 ± 0.5 with two products, 5.8 ± 0.6 with four products. Shared baseline 8.7 ± 0.4.Both adjunctive groups are marked significant versus standard care. Exact p values are unavailable.
VLDL cholesterol1.22 ± 0.06, 0.92 ± 0.07 and 0.87 ± 0.05 mmol/L, respectively. Shared baseline 1.42 ± 0.07.Both adjunctive groups are marked significant versus standard care.
Reported fatigue64.0%, 32.3% and 12.9%, respectively. Shared baseline 75.6%.Only the four-product group is marked significant versus standard care in the fatigue row.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. Symptom assessment and statistical methods are incompletely reported. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Source for these results ↗ · Reviewed 2026-11-16

Study limitations and source details

Study limitations

  • The authors excluded statin users and people with prior stroke. The comparison provides no individual estimates for Svetinorm or Endoluten.
  • Both editions name Svetinorm in the four-product group and outcome tables. The English dosing list instead says Suprefort. The schedule below follows the Russian methods.
  • The table gives one shared pretreatment column. Methods of allocation and masking, timing of the reported tables and adverse-event ascertainment are unspecified.
  • Table 1 repeats the triglyceride heading with values of unclear identity. The cholesterol, VLDL and first triglyceride rows are legible.
  • The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Source details

Conference report · company reproduction

Authors’ conference material, Russian reproduction, PDF pages 8–10, methods and Tables 1–2. English and Russian editions describe the same comparison.

Sources checked

Citation

Human comparative studyRussian-language source

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov. Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis 20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides.

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards